Replimune Group, Inc. filings document regulatory, financing, governance and operating disclosures for a Nasdaq-listed clinical-stage biotechnology company focused on oncolytic immunotherapies. Recent Form 8-K reports cover FDA communications involving the RP1 Biologics License Application, including complete response letters and related Regulation FD disclosures.
The filing record also documents quarterly financial results, corporate presentation materials for RP1 and RP2 programs, amendments to the company’s loan and security agreement, and annual meeting voting results. These disclosures describe Replimune’s development-stage operating profile, capital structure arrangements, stockholder governance matters and material events tied to its cancer immunotherapy pipeline.
Replimune Group, Inc. Chief Commercial Officer Christopher Sarchi sold 6,500 shares of common stock in an open-market transaction. The shares were sold on April 2, 2026 at a weighted average price of $8.01 per share, in multiple trades between $8.00 and $8.06.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025, indicating it was scheduled in advance. After this sale, Sarchi beneficially owns 151,588 shares of Replimune common stock, including restricted stock units, and holds options to acquire an additional 250,425 shares, 142,555 of which are currently exercisable.
REPL filed a Form 144 notice relating to proposed sales of Common shares. The filing lists a broker-dealer, J.P. Morgan Securities LLC, and includes a filing date of 04/02/2026. The excerpt shows scheduled RSU vesting entries on 11/15/2023, 11/15/2024, and 11/15/2025 with specified share amounts.
Replimune Group, Inc. director Philip Astley-Sparke reported a disposition of shares through a bona fide gift. He transferred 25,000 shares of Common Stock at a reported price of $0.00 per share, characterized as a gift transfer.
After this transaction, his directly held ownership was reported as 1,380,071 shares of Common Stock. The filing reflects a charitable or personal transfer rather than an open-market sale, so it does not indicate cash proceeds to the director.
Forbion Capital Fund III Cooperatief U.A. and Forbion III Management B.V. report their current ownership in Replimune Group, Inc. common stock. They beneficially own 2,808,368 shares, representing about 3.5% of the company’s outstanding common stock.
This percentage is based on 79,631,167 Replimune shares outstanding as of December 31, 2025, and reflects that the Reporting Persons now hold 5% or less of the class. All voting and investment power over these shares is shared, with no sole voting or dispositive authority reported.
Replimune Group reported a larger net loss as it continues investing heavily in its oncolytic immunotherapy pipeline. For the nine months ended December 31, 2025, the company recorded a net loss of $240.7 million, compared with $173.2 million a year earlier, driven mainly by higher research and development and selling, general and administrative expenses.
Cash and cash equivalents were $122.9 million and short‑term investments were $146.2 million as of December 31, 2025, and management believes this liquidity can fund operations for at least 12 months, including potential RP1 commercialization. The balance sheet also shows $47.6 million of long‑term debt with Hercules Capital and total lease liabilities of $28.7 million.
Clinically, the FDA issued a complete response letter for the RP1 BLA in advanced melanoma in July 2025, but later accepted a resubmitted BLA with a new PDUFA date of April 10, 2026. Replimune is running the Phase 3 IGNYTE‑3 confirmatory trial in anti‑PD‑1 failed melanoma and the REVEAL Phase 2/3 trial of RP2 in metastatic uveal melanoma.
The company also faces a putative securities class action, related shareholder derivative suits, a shareholder demand letter, and an SEC investigation focused on the RP1 BLA; Replimune denies wrongdoing and is cooperating with regulators.
Replimune Group, Inc. amended its Loan and Security Agreement with Hercules Capital and other lenders, extending a key revenue milestone date to September 30, 2027 and modifying several loan tranches. As part of this Third Amendment, the third loan tranche was increased to $35 million and fully funded on January 29, 2026.
The amendment adjusts future borrowing capacity and timing, including changes to the sizes and availability windows of the fourth, fifth, and sixth tranches, and sets the interest rate to the greater of 8.50% or the Prime Rate plus 1.75%. The loan amortization start date was pushed back from October 1, 2026 to October 1, 2027. The company also furnished a news release with financial results for the quarter ended December 31, 2025 as an exhibit.
Replimune Group, Inc. reported that it has released an updated corporate presentation covering recent business and strategic developments and clinical data for its RP1 and RP2 programs. The company plans to use this presentation in meetings with analysts, investors and others, including at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The slide deck is furnished as Exhibit 99.1, and a replay of the J.P. Morgan presentation webcast will be available on the company’s website under “Investors and Media” for 30 days. This information is furnished under Item 7.01 and is not deemed filed or incorporated by reference into other filings unless specifically stated.
Replimune Group, Inc. director reported an option exercise and share sale on 12/09/2025. The director exercised a stock option for 3,169 shares of common stock at an exercise price of $1.75 per share (transaction code M), then sold 3,169 shares of common stock at $10.4 per share the same day (transaction code S). After these transactions, the director reported beneficial ownership of 0 shares of common stock and 0 derivative securities from this option grant.
The disclosure explains that the option was exercised due to the upcoming 01/21/2026 expiration date, and that all 3,169 shares underlying this stock option had vested on 01/21/2016.
Replimune Group, Inc. (REPL) reported an insider transaction by its Chief Commercial Officer, who filed a Form 4 as a single reporting person. On 11/17/2025, the officer sold 5,208 shares of Replimune common stock in a transaction coded "S" for sale. The sale was executed at a broker-calculated weighted average price of $9.10 per share, with individual trades ranging from $8.88 to $9.26 per share.
The shares were sold solely to cover tax withholding obligations arising from the partial vesting of the officer’s restricted stock units under an irrevocable "sell to cover" provision, and are described as non-discretionary. Following this transaction, the officer beneficially owns 123,088 shares of Replimune common stock in direct ownership.
Replimune Group, Inc. (REPL) reported an insider transaction by its Chief Medical Officer. On 11/17/2025, the officer sold 7,248 shares of common stock in a transaction coded "S" at a weighted average price of $9.10 per share. The company explains this was an automatic sale to cover tax withholding obligations tied to the partial vesting of previously granted Restricted Stock Units under an irrevocable "sell to cover" provision, rather than a discretionary sale.
After this transaction, the officer beneficially owns 139,685 shares of Replimune common stock in direct ownership. The shares were sold as part of a block trade in multiple transactions at prices ranging from $8.88 to $9.26 per share, with detailed pricing information available on request.